T. Rowe Price Associates’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-18,200
| Closed | -$14K | – | 3002 |
|
|
2022
Q3 | $14K | Hold |
18,200
| – | – | ﹤0.01% | 2925 |
|
|
2022
Q2 | $21K | Hold |
18,200
| – | – | ﹤0.01% | 2920 |
|
|
2022
Q1 | $37K | Hold |
18,200
| – | – | ﹤0.01% | 2930 |
|
|
2021
Q4 | $52K | Hold |
18,200
| – | – | ﹤0.01% | 2921 |
|
|
2021
Q3 | $77K | Sell |
18,200
-5,400
| -23% | -$22.8K | ﹤0.01% | 2871 |
|
|
2021
Q2 | $125K | Sell |
23,600
-6,900
| -23% | -$36.5K | ﹤0.01% | 2807 |
|
|
2021
Q1 | $142K | Hold |
30,500
| – | – | ﹤0.01% | 2746 |
|
|
2020
Q4 | $101K | Sell |
30,500
-98,500
| -76% | -$326K | ﹤0.01% | 2623 |
|
|
2020
Q3 | $427K | Hold |
129,000
| – | – | ﹤0.01% | 2152 |
|
|
2020
Q2 | $435K | Buy |
129,000
+17,952
| +16% | +$60.5K | ﹤0.01% | 2100 |
|
|
2020
Q1 | $425K | Buy |
111,048
+41,300
| +59% | +$158K | ﹤0.01% | 2054 |
|
|
2019
Q4 | $421K | Buy |
69,748
+50,850
| +269% | +$307K | ﹤0.01% | 2211 |
|
|
2019
Q3 | $143K | Sell |
18,898
-21,294
| -53% | -$161K | ﹤0.01% | 2413 |
|
|
2019
Q2 | $545K | Sell |
40,192
-71,408
| -64% | -$968K | ﹤0.01% | 2073 |
|
|
2019
Q1 | $605K | Buy |
111,600
+70,400
| +171% | +$382K | ﹤0.01% | 2046 |
|
|
2018
Q4 | $122K | Sell |
41,200
-30,400
| -42% | -$90K | ﹤0.01% | 2462 |
|
|
2018
Q3 | $584K | Buy |
71,600
+13,400
| +23% | +$109K | ﹤0.01% | 2084 |
|
|
2018
Q2 | $567K | Buy |
58,200
+16,545
| +40% | +$161K | ﹤0.01% | 2075 |
|
|
2018
Q1 | $362K | Buy |
41,655
+23
| +0.1% | +$200 | ﹤0.01% | 2197 |
|
|
2017
Q4 | $521K | Buy |
+41,632
| New | +$521K | ﹤0.01% | 2062 |
|